SCHEMBL16963412

SCHEMBL16963412

O=C(CCc1ccc(-c2ccccn2)cc1)N1C[C@@H]2CN(C(=O)c3ccc4[nH]nnc4c3)C[C@H]2C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM5C P41229 4/20 0.41
▸ KDM4C Q9H3R0 4/20 0.41
▸ KDM2A Q9Y2K7 3/20 0.41
▸ KDM4A O75164 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ HTR2B P41595 1/20 0.41
▸ GHSR Q92847 1/20 0.41
▸ ABL1 P00519 3/20 0.40
▸ BCR P11274 3/20 0.40
▸ SLC6A7 Q99884 2/20 0.39
▸ NAMPT P43490 1/20 0.39
▸ KDM6B O15054 2/20 0.38
▸ KDM3A Q9Y4C1 2/20 0.38
▸ NPY5R Q15761 1/20 0.38
▸ GRIN2B Q13224 1/20 0.37
▸ HCAR2 Q8TDS4 1/20 0.36
▸ KDM2B Q8NHM5 1/20 0.36
▸ TGFBR1 P36897 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21322941 1.00 KDM5C (0.41) KDM5CKDM4CKDM2AKDM4AKDM4E
SCHEMBL16962981 0.89 NAAA (0.45) KDM5CKDM4CKDM2AKDM4AKDM4E
SCHEMBL18540872 0.89 NAAA (0.45) KDM5CKDM4CKDM2AKDM4AKDM4E
SCHEMBL20101595 0.89 HTR2B (0.49) HTR2BGHSRABL1BCRSLC6A7
SCHEMBL21323237 0.88 GHSR (0.39) KDM5CKDM4CKDM2AKDM4AKDM4E
SCHEMBL16962954 0.88 GHSR (0.39) KDM5CKDM4CKDM2AKDM4AKDM4E
SCHEMBL16963777 0.87 KDM5C (0.43) KDM5CKDM4CKDM2AKDM4AKDM4E
SCHEMBL21322925 0.87 KDM5C (0.43) KDM5CKDM4CKDM2AKDM4AKDM4E
SCHEMBL21323107 0.87 LSS (0.39) GHSR
SCHEMBL16963841 0.87 LSS (0.39) GHSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10669268-B2 Bicyclic derivatives HOFFMANN-LA ROCHE INC. (US) 2020-06-02 — — US claimed
EP-2900669-B1 HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AND RELATED COMPOUNDS AS AUTOTAXIN (ATX) INHIBITORS AND AS INHIBITORS OF THE LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION FOR TREATING E.G. RENAL DISEASES HOFFMANN LA ROCHE (CH) 2019-09-04 — — EP claimed
US-20180118741-A1 NEW BICYCLIC DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2018-05-03 — — US claimed
US-20150353559-A1 NEW BICYCLIC DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2015-12-10 — — US claimed
EP-2900669-A1 NEW BICYCLIC DERIVATIVES F. Hoffmann-La Roche AG (CH) 2015-08-05 — — EP claimed
US-20200339570-A1 BICYCLIC DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2020-10-29 — — US disclosed
US-20200339570-A1 BICYCLIC DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2020-10-29 — — US disclosed
US-10669268-B2 Bicyclic derivatives HOFFMANN-LA ROCHE INC. (US) 2020-06-02 — — US disclosed
EP-2900669-B1 HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AND RELATED COMPOUNDS AS AUTOTAXIN (ATX) INHIBITORS AND AS INHIBITORS OF THE LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION FOR TREATING E.G. RENAL DISEASES HOFFMANN LA ROCHE (CH) 2019-09-04 — — EP disclosed
US-20180118741-A1 NEW BICYCLIC DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2018-05-03 — — US disclosed
US-20170050960-A1 NEW BICYCLIC DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2017-02-23 — — US disclosed
US-20170050960-A1 NEW BICYCLIC DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2017-02-23 — — US disclosed
US-20170050960-A1 NEW BICYCLIC DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2017-02-23 — — US disclosed
US-20150353559-A1 NEW BICYCLIC DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2015-12-10 — — US disclosed
US-20150353559-A1 NEW BICYCLIC DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2015-12-10 — — US disclosed
US-20150353559-A1 NEW BICYCLIC DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2015-12-10 — — US disclosed
EP-2900669-A1 NEW BICYCLIC DERIVATIVES F. Hoffmann-La Roche AG (CH) 2015-08-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10669268-B2 Bicyclic derivatives CCNY, BICRA, UQCRB KDM5C 1449/4885KDM4C 674/4885KDM2A 1000/4885
US-20170050960-A1 NEW BICYCLIC DERIVATIVES BICRA, CCNY, UQCRB KDM5C 1570/4885KDM4C 728/4885KDM2A 1167/4885
US-20180118741-A1 NEW BICYCLIC DERIVATIVES BICRA, CCNY, UQCRB KDM5C 1570/4885KDM4C 728/4885KDM2A 1167/4885
US-20150353559-A1 NEW BICYCLIC DERIVATIVES BICRA, CCNY, UQCRB KDM5C 1570/4885KDM4C 728/4885KDM2A 1167/4885
US-20200339570-A1 BICYCLIC DERIVATIVES CCNY, BICRA, UQCRB KDM5C 1449/4885KDM4C 674/4885KDM2A 1000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback